Slayback Pharma launches Generic Zovirax Ointment for genital herpes in US

Slayback Pharma LLC has announced the launch of its new generic treatment for genital herpes, Generic Zovirax Ointment (Acyclovir Ointment) 5%, in the United States, marketed through an out-licensing agreement with Sandoz Inc., a generic pharmaceuticals subsidiary of Novartis AG.

Strategic Partnership and Market Entry

The launch follows the successful acquisition of an Abbreviated New Drug Application (ANDA) by Sandoz in May this year, which allows the sales and marketing rights of this product to be held by Sandoz. This approval marks a significant step in making effective treatments more accessible and affordable for patients suffering from genital herpes.

A Focus on Complex Generics

Ajay K Singh, CEO of Slayback Pharma, emphasized the company’s dedication to complex generics: “Slayback’s core focus is the development of complex generics primarily in parenteral and other non-solid pharmaceutical products by connecting the dots across various technologies, science, regulatory and intellectual property traditions. The successful development and approval of a complex generic formulation of Acyclovir Ointment meeting FDA’s standards is a testimony to this effort.”

Clinical Efficacy and Usage

Generic Zovirax Ointment is a generic version of the medication originally marketed by Valeant Pharmaceuticals. It is prescribed for the treatment of genital herpes and is also indicated for managing limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients. The ointment is advised to be used only on the affected skin area and should not come in contact with the eyes. It is important for patients to avoid using the ointment if they develop intolerance to any of its components.

Impact of Genital Herpes and Healthcare Implications

Genital herpes, caused by the herpes simplex virus (HSV), affects at least 50 million people in the US and poses significant health risks, including a doubled risk of contracting HIV. The introduction of a generic, more affordable version of this medication is crucial in managing this widespread and impactful disease.

Revenue Sharing and Future Prospects

While the specific terms of the agreement between Slayback Pharma and Sandoz were not disclosed, it is understood that Sandoz will continue to pay a share of the profits from the sale of the ointment to Slayback Pharma. This partnership not only benefits the companies involved but also supports public health by improving access to essential medications.

The launch of Generic Zovirax Ointment by Slayback Pharma and Sandoz marks a pivotal development in the treatment of genital herpes. By providing a generic option, they are making this crucial medication more accessible and affordable, potentially changing the treatment landscape for millions of Americans. This effort is an excellent example of how strategic partnerships in the pharmaceutical industry can address public health challenges effectively.